Under an agreement with Bayer, WuXi has taken over operations and assets of a drug substance facility located in Wuppertal, Germany, which includes three 1,000-L prefusion and six 2,000-L fed-batch bioreactors with independent downstream suites.

In March, WuXi acquired a biologics drug substance and product facility from Pfizer located in Hangzhou, China. This facility includes two 2,000-L single-use bioreactors that can be expanded to four bioreactors. The site also contains two drug product manufacturing facilities for drug product formulation and vial/syringe filling.

Lastly, WuXi acquired CMAB, which has operations in Suzhou, China. CMAB facilities include 7,000-L bioreactor drug substance capacity as well as drug product manufacturing for liquid and lyophilization fills. WuXi Biologics acquired 100% interest of CMAB, which will be renamed as WuXi Biologics (Suzhou) and operate as a wholly owned subsidiary.

With these acquisitions, WuXi Biologics has 11 facilities in China, the U.S., and Germany with a good manufacturing practice (GMP) manufacturing capacity of over 150,000-L. Moreover, the company will now have nine GMP drug product facilities for vials and syringes.